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Abstract
Background: Infection with HIV-1 may result in severe cognitive and motor impairment, referred to as HIV-1-associated
dementia (HAD). While its prevalence has dropped significantly in the era of combination antiretroviral therapy, milder
neurocognitive disorders persist with a high prevalence. To identify additional therapeutic targets for treating HIV-
associated neurocognitive disorders, several candidate gene polymorphisms have been evaluated, but few have been
replicated across multiple studies.
Methods: We here tested 7 candidate gene polymorphisms for association with HAD in a case-control study consisting of 86
HAD cases and 246 non-HAD AIDS patients as controls. Since infected monocytes and macrophages are thought to play an
important role in the infection of the brain, 5 recently identified single nucleotide polymorphisms (SNPs) affecting HIV-1
replication in macrophages in vitro were also tested.
Results: The CCR5 wt/D32 genotype was only associated with HAD in individuals who developed AIDS prior to 1991, in
agreement with the observed fading effect of this genotype on viral load set point. A significant difference in genotype
distribution among all cases and controls irrespective of year of AIDS diagnosis was found only for a SNP in candidate gene
PREP1 (p=1.2610
25). Prep1 has recently been identified as a transcription factor preferentially binding the 22,518 G allele
in the promoter of the gene encoding MCP-1, a protein with a well established role in the etiology of HAD.
Conclusion: These results support previous findings suggesting an important role for MCP-1 in the onset of HIV-1-
associated neurocognitive disorders.
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Introduction
While the prevalence of HIV-1-associated dementia (HAD) has
greatly decreased, first with the introduction of zidovudine [1,2]
and later with combination antiretroviral therapy (cART) [3,4],
neurocognitive impairment is still seen more frequently in HIV-1-
infected patients than in seronegative individuals. In recent years a
new terminology has been developed to classify this broadening
clinical spectrum of neurocognitive impairment, including milder
abnormalities. HAND (HIV-1-associated neurocognitive disor-
ders) is the umbrella definition, comprising three entities:
asymptomatic neurocognitive impairment, mild neurocognitive
disorders (MND), and HAD. Clinical symptoms of HAND are
cognitive impairment (memory, concentration), motor dysfunction
and behavioral changes. Recent studies showed that MND
occurred in 15–50% of the HIV-1-infected individuals [5–9],
and HAD in 1–10% of the patients [4,5,7,8].
Although CD4+ T cells are the predominant cell type infected
by HIV-1 and primarily associated with the disease course,
circulating monocytes as well as macrophages can also become
infected and contribute to the viral reservoir and disease
progression [10]. Furthermore, monocytes and macrophages play
a crucial role in certain HIV-1-related pathologies, including
HAND [10]. Despite lack of strong evidence it is generally
believed that HIV-1 migrates across the blood-brain barrier in
monocytes that were infected in the blood [11,12]. Indeed, in the
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30990brain, the monocyte-derived perivascular macrophages and
microglia are the most commonly HIV-1-infected cells [13,14].
Complex mechanisms underlie the neurodegeneration, since
neurons themselves are not infected by HIV-1. Local production
of HIV-1 proteins [15–18] or other non-HIV compounds [19–24]
by infected and activated macrophages and microglia cause
neuronal damage. Furthermore, neuronal injury may occur as a
consequence of the inflammatory process in the brain [25–27].
As is the case for many complex disorders, it remains unclear
why some individuals are more at risk to develop HAND than
others. The cause of the neurodegeneration is multi-factorial, and
in addition to viral genetic factors [28–30], host genetic
predisposition may also contribute to the susceptibility to these
disorders. We previously reported a reduced prevalence of the 32
base pair deletion in the CCR5 gene in HIV-infected individuals
with HAD as compared to controls with AIDS but no HAD [31],
and recently a single nucleotide polymorphism (SNP) in the gene
of one of its natural ligands, CCL3, was identified to be associated
with HAD as well [32]. SNPs in MCP-1 (monocyte chemoat-
tractant protein-1) and TNFA were found to affect protein
expression levels of these genes [33–36] and were associated with
the onset of HAD [34,37,38]. A biological mechanism by which
the SNP in MCP-1, located at position 22,518 in the promoter
region, affects gene expression was described recently [39]. This
study demonstrated that the transcription factor Prep1 preferen-
tially binds the 22,518 G allele in MCP-1, thereby affecting
transcription of this protein. Furthermore a SNP in CCR2,
encoding the receptor for MCP-1, was associated with rate of
progression to neuropsychological impairment [40]. However, few
of the associations between polymorphisms and HAD have been
replicated in other studies (see Table 1 for an overview of all
identified associations between host common genetic variants and
HAD).
Here, we evaluated the polymorphisms in previously tested
candidate genes CCR5, CCR2, MCP-1, TNFA, APOE and CCL3,a s
well as a polymorphism in the novel candidate gene PREP1, for
their association with HAD in participants of the Amsterdam
Cohort Studies of HIV infection and AIDS (ACS) and the AIDS
therapy evaluation in The Netherlands (ATHENA) observational
cohort. In addition, given the important role of monocytes and
macrophages in the etiology of HAD, SNPs that we recently
identified to affect HIV-1 replication in macrophages in vitro were
also tested [41].
Materials and Methods
Ethics statement
This study has been conducted in accordance with the ethical
principles set out in the declaration of Helsinki. Anonymized
archival material (peripheral blood mononuclear cells or DNA)
from AIDS patients was used in this study, which was approved by
the Medical Ethics Committee of the Academic Medical Center in
Amsterdam, The Netherlands. For the qPCR experiments,
anonymized buffy coat or full blood was used from healthy blood
donors, and the use was approved by the Medical Ethics
Committee of the Academic Medical Center and the Ethics
Advisory Body of the Sanquin Blood Supply Foundation in
Amsterdam, The Netherlands. Written informed consent was
obtained from all of these healthy donors.
Study population
In total we selected 86 AIDS patients with HAD (cases) from the
Amsterdam Cohort Studies and ATHENA observational cohort
from whom DNA was available for genotyping. Before the AIDS
dementia complex was defined as a distinct clinical syndrome the
diagnosis of dementia in these patients had been based on DSM-
III (Diagnostic and Statistical Manual of Mental Disorders)
criteria. Motor abnormalities were present in all these demented
patients, which agreed retrospectively with the diagnostic criteria
of the AIDS dementia complex [42]. When more precise
Table 1. Overview of all common genetic variants tested for association with HIV-1-associated neurocognitive disorders.
Gene Polymorphism Association with HAND No association with HAND
APOE E4 isoform Corder et al. [60], HAD; prospective
cohort study (n=44)
Pemberton et al. [61], HAD; 56 cases, 112 controls
Diaz-Arrastia et al. [62], HIVE; cohort A: 43 cases and
104 controls, and cohort B: 14 cases and 117 controls
Dunlop et al. [63], HAD and HIVE; 32 HAD cases,
24 possible HAD cases and 73 controls
CCL3 rs1130371 Levine et al. [32], HAD; 26 cases, 117 controls
CCR2 rs1799864
V64I
Singh et al. [40], HAND, prospective
cohort study (n=121)
Van Rij et al. [31], HAD; 49 cases, 186 controls
CCR5 D32 Van Rij et al. [31], HAD; 49 cases, 186 controls Singh et al. [40], HAND, prospective cohort study (n=121)
MCP-1 rs1024611
(22518 A.G)
Gonzalez et al. [34], HAD; prospective
cohort study (n=1,115)
Singh et al. [40], HAND, prospective
cohort study (n=121)
Shiramizu et al. [37], HIV-1 DNA in
CSF; 27 specimens
Levine et al. [32], HAD; 26 cases, 117 controls
TNFA rs1800629
(2308 G.A)
Quasney et al. [38], HAD; 16
cases, 45 controls
Sato-Matsumura et al. [64], HIVE;
44 cases, 30 controls
Pemberton et al. [61], HAD; 56
cases, 112 controls
Levine et al. [32], HAD; 26 cases, 117 controls
Diaz-Arrastia et al. [62], HIVE; cohort A: 43 cases and
104 controls, and cohort B: 14 cases and 117 controls
HAND, HIV-1-associated neurocognitive disorders; HAD, HIV-1-associated dementia; HIVE, HIV-1 encephalitis.
doi:10.1371/journal.pone.0030990.t001
SNP in PREP1 Associated with HAD
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these criteria were used to classify these patients. The absence of
dementia was confirmed by neurological examination by a
neurologist.
We compared the HAD patients with 246 AIDS patients
without HAD (controls) (Table 2). A subset of these samples (49
cases and 186 controls) was included in a previous study that
investigated CCR5 D32 and CCR2 V64I genotype frequencies
between HAD cases and controls [31].
Cases and controls were matched for year of AIDS diagnosis
(AIDS diagnosis was based on AIDS defining events according to
the CDC AIDS definition 1987; Kaposi’s sarcoma was excluded as
an AIDS defining event), time from AIDS diagnosis to death or to
start of combination antiretroviral therapy (cART), age at AIDS
diagnosis and CD4+ T cell count at AIDS diagnosis. Cases
receiving cART more than 6 months before their HAD diagnosis
(n=14), as well as controls who started cART more than 6 months
before their AIDS diagnosis (n=5) were excluded from the
analysis. Median time from AIDS to developing HAD for the cases
was significantly shorter than the time from AIDS to death or to
start cART in the control population (p,0.0001; Mann Whitney
test) (Table 2), indicating that time from AIDS to death or to start
cART for the HIV-1-infected individuals in the control group was
in principle long enough to develop HAD. Similar results were
obtained when using Kaplan-Meier analysis, with no difference in
time from AIDS to death (start cART used as censor) between
cases and controls (p=0.11, logrank test) and significant shorter
time from AIDS to HAD for the cases, than time from AIDS to
death (start cART as censor) for the controls (p=0.00036, logrank
test) (Figure 1A–B). Information on ancestry was only known for
a limited number of patients and was based on reported ethnicity
by the treating physician or reported country of birth.
Candidate SNP selection and genotyping
Genotype distributions of polymorphisms previously associated
with HAND (Table 1) as well as SNPs associated with in vitro
HIV-1 replication in macrophages (cutoff p value=5610
25)
(Table S1) [41], were analyzed in this case-control study. PREP1
Table 2. Characteristics of the studied population consisting of AIDS patients with or without HAD.
Characteristics HAD patients Non-HAD patients p
(cases, n=72) (controls, n=241)
AIDS diagnosis (year); median (range) 1989 (1984–2005) n=69 1990 (1985–2005) n=241 –
Time AIDS to death or start cART (months); median (range) 14 (0–114) n=67 12 (0–81) n=234 0.21
1
Time AIDS to HAD (months); median (range) 5 (0–114) n=69 N.A. ,0.0001
1,2
Age at diagnosis AIDS; average (range) 40 (22–63) n=69 41 (23–71) n=241 0.60
3
CD4+ T cell count (cells/ml) at AIDS, median (range)
4 120 (10–850) n=39 105 (7–1,380) n=166 0.48
1
Mode of HIV-1 transmission (IDU : other) 4 : 35 4 : 158 0.048
5
N.A., not applicable; HAD, HIV-1-associated dementia; IDU, injecting drug user.
1Mann Whitney test.
2Time to develop HAD after AIDS diagnosis among the cases was compared to the time from AIDS diagnosis to death or to start cART in the control group.
3unpaired t test.
4CD4+ T cell counts within 6 months to the date of AIDS diagnosis.
5Fisher’s exact test.
doi:10.1371/journal.pone.0030990.t002
Figure 1. Comparison of AIDS survival between HAD cases and non-HAD controls. (A) Kaplan Meier analysis for time from AIDS to death
with start cART as censor (vertical lines), for both HAD cases (grey line) and non-HAD AIDS patients as controls (black line). (B) Kaplan Meier analysis
for time from AIDS to death with start cART as censor (vertical lines) for the controls (black line) and for time from AIDS to HAD for the HAD cases
(grey line). cART, combination antiretroviral therapy; HAD, HIV-1-associated dementia.
doi:10.1371/journal.pone.0030990.g001
SNP in PREP1 Associated with HAD
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allele in the promoter region of MCP-1. SNP rs2839619 was
selected from 17 SNPs in PREP1 after preliminary analysis
comparing 15 cases with 126 unmatched controls. This SNP seems
of particular interest since it was shown to be associated with
cholesterol metabolism [45], which is known to play a role in the
etiology of Alzheimer’s disease [46] and in addition, is in linkage
disequilibrium (r
2=0.51) with nearby intronic SNP rs234720 that
has been associated with cognitive test performance [47].
Peripheral blood mononuclear cells were used for isolation of
genomic DNA using QIAamp DNA blood mini kit (Qiagen,
Valencia, CA, USA) or NucleoSpin blood kit (Macherey-Nagel,
Dueren, Germany). SNP genotypes for SNPs in DYRK1A, PDE8A,
UBR7 and PREP1 (Table S1) were available for 172 individuals
(18 cases, 154 controls) from a recent study on the effects of host
genetic variation on HIV-1 susceptibility and disease progression
[48]. For the remaining DNA samples and other SNPs not present
on the Illumina SNP beadchip, ABI TaqManH SNP genotyping
assays (Applied Biosystems, Carlsbad, CA, USA) were used for
genotyping (Table S1). For all SNPs except the SNP in TNFA,
genotyping assays were run on a LightCyclerH 480 system (Roche,
Basel, Switzerland) using Probes Master (Roche) with the following
amplification cycles: 10 min 95uC; 50 cycles of 15 sec 95uC, 1 min
60uC.
The TNFA SNP assay was run on an Applied Biosystems 7500
Fast Real-Time PCR System (Applied Biosystems) with Taqman
genotyping master mix (Applied Biosystems), and using the
following amplification cycles: 10 min 95uC; 40 cycles of 15 sec
95uC, 1 min 60uC. APOE allele types (E2, E3 or E4 [49]) were
determined by genotyping SNPs rs429358 (C or T) and rs7412 (C
or T). CCR5 D32 and CCR2 V64I genotyping was performed as
described previously [50,51].
Quantitative PCR
Buffy coat or full blood was obtained from 69 healthy blood
donors. Monocyte isolation and monocyte-derived macrophage
(MDM) culture was performed as previously described [52]. Total
RNA was extracted from day 7 uninfected MDM using the High
Pure RNA Isolation kit (Roche). Oligo(dT) primers were used for
reverse transcription of mRNA, using Roche’s Transcriptor First
Strand cDNA Synthesis kit (60 min at 50uC). Resulting cDNA was
used for quantitative PCR (qPCR) analysis, using the following
primes: PREP1 F and R, MCP-1 F and R, and GAPDH F and R
(Table S2). qPCRs were performed with SYBR Green I Master
(Roche) and were run on a LightCyclerH 480 system (Roche) using
the following amplification cycles: 10 min 95uC; 50 cycles of
10 sec 95uC, 20 sec 58uC, 30 sec 72uC. All procedures were
carried out according to manufacturer’s protocol. Messenger RNA
expression is reported relative to GAPDH. Gene expression values
were obtained using Roche’s LightCyclerH relative quantification
software (release 1.5.0). To facilitate accurate and reliable
between-donor comparison, cDNA synthesis and qPCR experi-
ments for all 69 samples were performed simultaneously.
Statistical analysis
Fisher’s exact test was used to test for differences in SNP
genotype distribution between cases and controls. To test for
differences in group characteristics between cases and controls the
Mann Whitney test and the unpaired t test were used. One-way
ANOVA was performed to test for differences in mRNA levels
between genotypes. Statistical analysis was performed using the
statistical computing software R (version 2.9.0) and GraphPad
Prism (version 5).
Results
Genotype frequencies for all polymorphisms tested, in the group
of cases with HAD (n=72) and the group of controls that did not
develop HAD (n=241), are displayed in Table 3. Of the 12
polymorphisms tested, a significant difference in genotype
distribution for SNP rs2839619 in PREP1 was found between
cases and controls (p=1.2610
25; 71 cases and 235 controls; DNA
was limited for some of the cases or controls, therefore not all
samples could always be genotyped). The difference remained
statistically significant after Bonferroni correction for multiple
comparisons (n=12), p=1.461024. Also after excluding HAD
Table 3. Genotype distribution among HAD (cases) and non-HAD (controls) HIV-1-infected patients for all polymorphisms tested.
Gene Polymorphism Cases (HAD) Controls (no HAD) p
AA AB BB AA AB BB
APOE
1 E4 isoform
2 52 16 1 158 52 5 0.95
CCL3
1 rs1130371 40 26 5 133 90 9 0.53
CCR2
1 rs1799864 (V64I) 64 8 0 206 34 1 0.66
CCR5
1 D32 66 6 0 203 38 0 0.13
DYRK1A
3 rs12483205 38 25 8 125 96 11 0.13
MCP-1
1 rs1024611 (22518 A.G) 3 27 41 14 101 116 0.58
MOAP1
3 rs1046099 29 36 6 117 93 20 0.28
PDE8A
3 rs12909130 33 34 4 110 96 26 0.34
PREP1 rs2839619 30 17 24 55 130 50 1.2610
25*
SPOCK3
1 rs17519417 21 32 17 76 102 53 0.91
TNFA
1 rs1800629 (2308 G.A)(2308 G.A) 57 13 1 158 62 9 0.20
UBR7
3 rs2905 10 28 33 22 107 103 0.42
1Polymorphisms selected from earlier studies that tested for association between genotype and HAD.
2In the case of APOE AA, AB and BB refer to no APO E4, one APO E4 allele and two APO E4 alleles, respectively.
3SNPs selected from a previous study that found associations between these SNPs and HIV-1 replication in macrophages.
*Significant difference after correction for multiple testing (n=12); Bonferroni threshold p=4.2 610
23.
doi:10.1371/journal.pone.0030990.t003
SNP in PREP1 Associated with HAD
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drug use was reported as mode of HIV-1 transmission, a known
risk factor for HAD [4], the difference in PREP1 SNP genotype
distribution between cases (n=64) and controls remained
significant (n=211) (p=4.3610
25). Quantitative PCR experi-
ments performed to investigate if the SNP in PREP1 was
associated with either PREP1 or MCP-1 mRNA levels showed
no difference in PREP1 or MCP-1 mRNA levels between the three
PREP1 SNP genotypes (p=0.3 and 0.8, respectively, n=69; one-
way ANOVA) (data not shown).
Remarkably, for none of the other polymorphisms tested,
including those previously reported to be associated with HAD
(CCR5 D32, promoter SNP in MCP-1, the 2308 G.A SNP in
TNFA, CCR2 V64I variant, Apo E4 isoform and a SNP in CCL3), a
significant difference was found in genotype distribution between
cases and controls. In a previous case-control study [31], we
described a reduced prevalence of the CCR5 wt/D32 genotype
among HAD patients. A subset of cases and controls from this
published study overlaps with our current study population. Cases
and controls that were additionally included for this study
seroconverted on average later in time. We recently reported that
in the HIV-1 epidemic in The Netherlands, the impact of certain
host factor polymorphisms, including CCR5 D32, might be fading
[53]. We therefore hypothesized that the protective impact of the
CCR5 wt/D32 genotype on the onset of HAD also may have
decreased over time. To test this hypothesis we divided cases and
controls into two groups using the median year of AIDS diagnosis
of the complete study population (1990). This approach was
chosen over using seroconversion date since this information was
unavailable for 29 of 42 cases with AIDS diagnosis #1990.
Importantly, cases and controls with AIDS diagnosis #1990 as
well as with AIDS diagnosis .1990 matched all of the
characteristics as described above (Table S4), and time from
AIDS to death or to start cART for the HIV-1-infected individuals
in the control group was in principle long enough to develop HAD
(p=0.005 and p=0.001 for cases and controls with AIDS
diagnosis #1990 and .1990, respectively, Mann Whitney test)
(Table S4). Similar results were obtained when using Kaplan-
Meier analysis and logrank test (data not shown). When the CCR5
wt/D32 genotype frequency was compared between cases and
controls we observed a difference in the ‘‘AIDS diagnosis #1990’’
group (p=0.046), but not for the ‘‘AIDS diagnosis .1990’’ group
(p=1.00) (Table S3), indeed suggestive of a fading protective
effect. Assuming that other genetic effects may also have
diminished over time in our cohort, we performed the same
analysis for the remaining polymorphisms (Table S3). For 9
polymorphisms, no significant associations were observed in either
group. The effect of the SNP in PREP1 was clearly independent of
the year of AIDS diagnosis, since in both groups there were
significantly fewer heterozygous individuals for SNP rs2839619
among cases than controls (p=0.001 and p=0.008 for the ‘‘AIDS
diagnosis #1990’’ and the ‘‘AIDS diagnosis .1990 group’’,
respectively) (Table S3). Conversely, a significant (defined as
p,0.05; however not significant after correction for multiple
testing, n=24) association with HAD was observed for the SNP in
DYRK1A only in the group with AIDS diagnosis after 1990.
Discussion
Here we describe the first combined evaluation of all previously
identified genetic polymorphisms reported to be associated with
the prevalence of HAND. In addition, we evaluated polymor-
phisms that we recently identified to be associated with HIV-1
replication in macrophages for their association with HAD. For
one of the 12 polymorphisms tested, SNP rs2839619 in PREP1,w e
observed a significantly different genotype distribution when
comparing AIDS patients with and without HAD. The prevalence
of the heterozygous genotype was 55% among controls (and 53%
in the HapMap CEU population, n=226), as compared to only
24% among HAD cases, suggesting that the heterozygous
genotype has a protective effect against the development of
HAD (positive heterosis). Although multiple examples of heterosis
exist ([54,55] and reviewed in [56]), the molecular basis for this
heterozygous effect sometimes remains difficult to understand
(reviewed in [56,57]).
Case-control studies are greatly influenced by variation in allele
frequency across different subgroups [58] that may lead to
identification of false positive associations. However, the associa-
tion for the PREP1 SNP remained significant after excluding
patients expected to be of non-European descent. Moreover, since
the allele frequency for this SNP is similar for Caucasians, Asians
and Africans (NCBI dbSNP) we do not expect that additional
population stratification resulting from ethnicity would affect this
association. Differences in population substructure may be of
importance when SNP rs2839619 is not the causal variant but
rather tags another genetic variant, since for that particular SNP
genotype distributions may vary between different populations. In
addition, the outcome remained unaffected after correcting for
injecting drug use as mode of HIV-1 transmission. Although it is
known that Prep1 binds to the promoter region of MCP-1,w e
were unable to demonstrate an association between SNP genotype
and MCP-1 mRNA levels in MDM. However, MCP-1 is secreted
by monocytes and macrophages, but expression is not limited to
these cell-types. The cytokine is also expressed in for HAD possibly
more relevant cells such as endothelial cells, astrocytes, microglia
and neurons ([59] and references therein). Functional follow-up
studies will need to delineate a mechanism that helps to explain the
observed reduced frequency of heterozygous donors in the group
of HAD patients.
None of the previously identified associations between genetic
variants and HAND could be replicated in our present study, even
when tested under a dominant or recessive model (data not
shown). Many of the candidate gene polymorphisms suggested to
play a role in the prevalence of HAND have not been reproduced
widely in other cohorts (Table 1). Limitations in the availability of
patient material, heterogeneity in HAND diagnoses, differences in
case-control matching strategies and possible population substruc-
ture may have contributed to the absence of robust and replicable
results. While we tried to carefully address many of these issues in
this study, no robust replication of the reported associations was
obtained, suggesting that meta-analyses of multiple HAND
cohorts may be required to reliably evaluate the effect of host
polymorphisms on HAND.
SNPs previously associated with HIV-1 Gag p24 levels in
macrophage cultures were not found to be associated with HAD,
although meta-analyses may be required to firmly establish this.
This possibly suggests that the quantity of HIV-1 replication in
macrophages is less important for the etiology of this phenotype as
compared to the immune activation in the brain as a consequence
of HIV-1 replication [12].
The protective effect observed for the CCR5 wt/D32 genotype
was only observed in the group of individuals that had an AIDS
diagnosis #1990 and no longer in the group that was diagnosed
with AIDS .1990. Excluding cases and control from non-
European descent, in whom the CCR5 wt/D32 genotype is less
frequent, did not change the outcome of the analysis. In agreement
with these findings, we observed a similar fading impact of the
SNP in PREP1 Associated with HAD
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at a population level [53].
We also observed a difference in DYRK1A SNP rs12483205
genotype distribution between cases and controls with AIDS
diagnosis #1990. While the minor allele of this SNP was
associated with reduced replication of HIV-1 in monocyte-derived
macrophages in vitro [41] the observed difference here is the result
of 35% more cases homozygous for the major allele, yet 59%
fewer cases with the heterozygous genotype as compared to the
controls (data not shown). This difference could possibly be due to
population stratification since in both Asian and sub-Saharan
African populations the frequency of the homozygous major and
heterozygous genotype is higher and lower respectively (dbSNP).
The association of a SNP in PREP1 with the onset of HAD
further supports the biological importance of MCP-1 in the
pathogenesis of this disease. Replication of this association in an
independent cohort using matched HAD cases and controls will
now be highly desirable. Functional studies will be required to
delineate how the observed difference in allele frequencies can be
explained in a biological context.
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